Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
137.75
+8.65 (6.70%)
At close: Feb 21, 2025, 4:00 PM
138.95
+1.20 (0.87%)
After-hours: Feb 21, 2025, 6:21 PM EST
Axsome Therapeutics Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Axsome Therapeutics stock have an average target of 158.93, with a low estimate of 105 and a high estimate of 200. The average target predicts an increase of 15.38% from the current stock price of 137.75.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Axsome Therapeutics stock from 14 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 7 | 7 | 6 |
| Buy | 6 | 6 | 6 | 7 | 7 | 8 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $200 | Strong Buy | Maintains | $200 | +45.19% | Feb 20, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $190 → $200 | Strong Buy | Maintains | $190 → $200 | +45.19% | Feb 19, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $143 → $192 | Buy | Maintains | $143 → $192 | +39.38% | Feb 19, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $153 | Buy | Reiterates | $153 | +11.07% | Feb 19, 2025 |
| Needham | Needham | Strong Buy Maintains $133 → $153 | Strong Buy | Maintains | $133 → $153 | +11.07% | Feb 19, 2025 |
Financial Forecast
Revenue This Year
392.86M
from 270.60M
Increased by 45.18%
Revenue Next Year
649.07M
from 392.86M
Increased by 65.22%
EPS This Year
-5.58
from -5.27
EPS Next Year
-2.40
from -5.58
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 409.6M | 810.5M | 1.3B | |||
| Avg | 392.9M | 649.1M | 1.1B | |||
| Low | 371.1M | 534.1M | 835.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 51.4% | 106.3% | 97.1% | |||
| Avg | 45.2% | 65.2% | 62.7% | |||
| Low | 37.2% | 36.0% | 28.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -5.06 | -0.29 | 6.62 | |||
| Avg | -5.58 | -2.40 | 3.15 | |||
| Low | -5.93 | -4.51 | -0.54 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.